Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:ISRG's Cash to Debt is ranked higher than
98% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NAS:ISRG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:ISRG' s Cash to Debt Range Over the Past 10 Years
Min: 12.85  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.90
NAS:ISRG's Equity to Asset is ranked higher than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:ISRG: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ISRG' s Equity to Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 0.9
Current: 0.9
0.7
0.9
Interest Coverage No Debt
NAS:ISRG's Interest Coverage is ranked higher than
97% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. NAS:ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 7
Z-Score: 25.10
M-Score: -2.35
WACC vs ROIC
8.30%
24.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 35.32
NAS:ISRG's Operating margin (%) is ranked higher than
99% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NAS:ISRG: 35.32 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ISRG' s Operating margin (%) Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 35.32
25.56
40.3
Net-margin (%) 27.51
NAS:ISRG's Net-margin (%) is ranked higher than
96% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NAS:ISRG: 27.51 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ISRG' s Net-margin (%) Range Over the Past 10 Years
Min: 19.33  Med: 24.38 Max: 30.14
Current: 27.51
19.33
30.14
ROE (%) 15.10
NAS:ISRG's ROE (%) is ranked higher than
81% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NAS:ISRG: 15.10 )
Ranked among companies with meaningful ROE (%) only.
NAS:ISRG' s ROE (%) Range Over the Past 10 Years
Min: 12.17  Med: 18.96 Max: 21.36
Current: 15.1
12.17
21.36
ROA (%) 13.44
NAS:ISRG's ROA (%) is ranked higher than
91% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NAS:ISRG: 13.44 )
Ranked among companies with meaningful ROA (%) only.
NAS:ISRG' s ROA (%) Range Over the Past 10 Years
Min: 10.59  Med: 16.51 Max: 18.44
Current: 13.44
10.59
18.44
ROC (Joel Greenblatt) (%) 155.63
NAS:ISRG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NAS:ISRG: 155.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ISRG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 114.4  Med: 186.03 Max: 245.9
Current: 155.63
114.4
245.9
Revenue Growth (3Y)(%) 5.90
NAS:ISRG's Revenue Growth (3Y)(%) is ranked higher than
59% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NAS:ISRG: 5.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ISRG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 20.1 Max: 57.1
Current: 5.9
0
57.1
EBITDA Growth (3Y)(%) -1.30
NAS:ISRG's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NAS:ISRG: -1.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ISRG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.8  Med: 29.65 Max: 318.7
Current: -1.3
-62.8
318.7
EPS Growth (3Y)(%) -0.90
NAS:ISRG's EPS Growth (3Y)(%) is ranked lower than
53% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NAS:ISRG: -0.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ISRG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.5  Med: 23.85 Max: 76.8
Current: -0.9
-61.5
76.8
» NAS:ISRG's 10-Y Financials

Financials (Next Earnings Date: 2017-01-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ISRG Guru Trades in Q4 2015

Louis Moore Bacon 18,000 sh (New)
Paul Tudor Jones 1,800 sh (New)
Steven Cohen 58,700 sh (+615.85%)
Vanguard Health Care Fund 519,996 sh (+18.13%)
Samuel Isaly 80,000 sh (unchged)
John Hussman Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc 541,435 sh (-9.04%)
Jeremy Grantham 77,879 sh (-9.24%)
Robert Olstein 11,000 sh (-12.00%)
Jim Simons 109,170 sh (-46.11%)
Ray Dalio 2,024 sh (-74.13%)
» More
Q1 2016

ISRG Guru Trades in Q1 2016

Pioneer Investments 6,794 sh (New)
Ray Dalio 6,124 sh (+202.57%)
Samuel Isaly 84,000 sh (+5.00%)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jim Simons 107,770 sh (-1.28%)
Jeremy Grantham 75,598 sh (-2.93%)
Vanguard Health Care Fund 456,850 sh (-12.14%)
Robert Olstein 9,400 sh (-14.55%)
Manning & Napier Advisors, Inc 195,125 sh (-63.96%)
Paul Tudor Jones 600 sh (-66.67%)
» More
Q2 2016

ISRG Guru Trades in Q2 2016

RS Investment Management 10,680 sh (New)
Joel Greenblatt 13,254 sh (New)
Steven Cohen 13,500 sh (New)
Jeremy Grantham 91,193 sh (+20.63%)
Samuel Isaly 110,000 sh (+30.95%)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 428,750 sh (-6.15%)
Manning & Napier Advisors, Inc 175,705 sh (-9.95%)
Robert Olstein 8,000 sh (-14.89%)
Pioneer Investments 3,708 sh (-45.42%)
Jim Simons 32,238 sh (-70.09%)
» More
Q3 2016

ISRG Guru Trades in Q3 2016

Ray Dalio 7,400 sh (New)
Lee Ainslie 1,750 sh (New)
Jim Simons 82,270 sh (+155.20%)
Pioneer Investments 3,708 sh (unchged)
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc 165,220 sh (-5.97%)
Robert Olstein 7,000 sh (-12.50%)
Jeremy Grantham 69,164 sh (-24.16%)
Vanguard Health Care Fund 243,169 sh (-43.28%)
Steven Cohen 3,900 sh (-71.11%)
Samuel Isaly 56,174 sh (-48.93%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:STJ, NYSE:BSX, NYSE:ZBH, NYSE:EW, OTCPK:SNNUF, NYSE:SYK, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO, NAS:WMGI, NYSE:PEN » details
Traded in other countries:IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Intuitive Surgical Inc designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.

Intuitive Surgical Inc is a Delaware corporation founded in 1995. The Company designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories. A da Vinci Surgical System consists of a surgeon's console, a patient-side cart, and a high performance vision system. da Vinci Surgery utilizes computational, robotic and imaging technologies to enable improved patient outcomes compared to other surgical and non-surgical therapies. The Company has commercialized four generations of da Vinci Surgical System- the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. da Vinci Surgical Systems are comprised of the following components: Surgeon's Console. The da Vinci Surgical System allows surgeons to operate while comfortably seated at an ergonomic console viewing a 3-D image of the surgical field. Patient-Side Cart. The patient-side cart holds electromechanical arms that manipulate the instruments inside the patient. 3-D Vision System. Its vision system includes its InSite 3-D endoscope with two separate vision channels linked to two separate color monitors through high performance video cameras and specialized image processing hardware. da Vinci Skills Simulator. The Skills Simulator is a practice tool that gives a user the opportunity to practice his or her facility with the surgeon console controls. EndoWrist instruments are offered in a variety of sizes, of which 5mm and 8mm diameter sizes are commonly sold. The Company provides its products through a direct sales organization in the U.S, mainly of Western Europe excluding Spain, Portugal, Italy and Greece; Japan and Korea. The Company's products and operations are subject to rigorous regulation by the FDA, the State of California and countries or regions in which the company markets its products.

Ratios

vs
industry
vs
history
P/E(ttm) 33.93
ISRG's P/E(ttm) is ranked lower than
62% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. ISRG: 33.93 )
Ranked among companies with meaningful P/E(ttm) only.
ISRG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.77  Med: 37.72 Max: 107.2
Current: 33.93
17.77
107.2
Forward P/E 25.06
ISRG's Forward P/E is ranked lower than
59% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. ISRG: 25.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.93
ISRG's PE(NRI) is ranked lower than
63% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. ISRG: 33.93 )
Ranked among companies with meaningful PE(NRI) only.
ISRG' s PE(NRI) Range Over the Past 10 Years
Min: 17.77  Med: 37.72 Max: 107.2
Current: 33.93
17.77
107.2
Price/Owner Earnings (ttm) 33.96
ISRG's Price/Owner Earnings (ttm) is ranked lower than
58% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 30.39 vs. ISRG: 33.96 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ISRG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.18  Med: 41.14 Max: 110.28
Current: 33.96
18.18
110.28
P/B 4.41
ISRG's P/B is ranked lower than
64% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. ISRG: 4.41 )
Ranked among companies with meaningful P/B only.
ISRG' s P/B Range Over the Past 10 Years
Min: 2.81  Med: 6.07 Max: 15.72
Current: 4.41
2.81
15.72
P/S 9.30
ISRG's P/S is ranked lower than
84% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. ISRG: 9.30 )
Ranked among companies with meaningful P/S only.
ISRG' s P/S Range Over the Past 10 Years
Min: 4.16  Med: 9.79 Max: 24.28
Current: 9.3
4.16
24.28
PFCF 25.83
ISRG's PFCF is ranked higher than
50% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. ISRG: 25.83 )
Ranked among companies with meaningful PFCF only.
ISRG' s PFCF Range Over the Past 10 Years
Min: 18.41  Med: 32.22 Max: 128.48
Current: 25.83
18.41
128.48
POCF 24.40
ISRG's POCF is ranked lower than
68% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. ISRG: 24.40 )
Ranked among companies with meaningful POCF only.
ISRG' s POCF Range Over the Past 10 Years
Min: 11.34  Med: 27.63 Max: 84.53
Current: 24.4
11.34
84.53
EV-to-EBIT 23.91
ISRG's EV-to-EBIT is ranked lower than
57% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. ISRG: 23.91 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.7 Max: 74.4
Current: 23.91
10.2
74.4
EV-to-EBITDA 21.75
ISRG's EV-to-EBITDA is ranked lower than
67% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. ISRG: 21.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.5  Med: 24.15 Max: 61.7
Current: 21.75
9.5
61.7
PEG 7.15
ISRG's PEG is ranked lower than
80% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ISRG: 7.15 )
Ranked among companies with meaningful PEG only.
ISRG' s PEG Range Over the Past 10 Years
Min: 0.15  Med: 0.98 Max: 18.34
Current: 7.15
0.15
18.34
Shiller P/E 54.21
ISRG's Shiller P/E is ranked lower than
59% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. ISRG: 54.21 )
Ranked among companies with meaningful Shiller P/E only.
ISRG' s Shiller P/E Range Over the Past 10 Years
Min: 44.02  Med: 73.79 Max: 282.23
Current: 54.21
44.02
282.23
Current Ratio 5.51
ISRG's Current Ratio is ranked higher than
82% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ISRG: 5.51 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.63 Max: 7.43
Current: 5.51
2.07
7.43
Quick Ratio 5.17
ISRG's Quick Ratio is ranked higher than
84% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. ISRG: 5.17 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.33 Max: 7.07
Current: 5.17
1.72
7.07
Days Inventory 79.85
ISRG's Days Inventory is ranked higher than
74% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. ISRG: 79.85 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 55.48  Med: 71.72 Max: 91.85
Current: 79.85
55.48
91.85
Days Sales Outstanding 60.09
ISRG's Days Sales Outstanding is ranked higher than
62% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. ISRG: 60.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 62.89 Max: 92.73
Current: 60.09
48.57
92.73
Days Payable 27.57
ISRG's Days Payable is ranked lower than
81% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ISRG: 27.57 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 32.95 Max: 58.29
Current: 27.57
23.81
58.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.40
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ISRG: 2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -2.7 Max: 2.4
Current: 2.4
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.29
ISRG's Price/Net Cash is ranked higher than
52% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 16.84 vs. ISRG: 15.29 )
Ranked among companies with meaningful Price/Net Cash only.
ISRG' s Price/Net Cash Range Over the Past 10 Years
Min: 2.88  Med: 20.72 Max: 333.4
Current: 15.29
2.88
333.4
Price/Net Current Asset Value 10.62
ISRG's Price/Net Current Asset Value is ranked lower than
69% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 6.51 vs. ISRG: 10.62 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISRG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.21  Med: 12.24 Max: 28.5
Current: 10.62
2.21
28.5
Price/Tangible Book 4.65
ISRG's Price/Tangible Book is ranked lower than
56% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. ISRG: 4.65 )
Ranked among companies with meaningful Price/Tangible Book only.
ISRG' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.05  Med: 5.95 Max: 16.47
Current: 4.65
2.05
16.47
Price/Projected FCF 1.99
ISRG's Price/Projected FCF is ranked lower than
52% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. ISRG: 1.99 )
Ranked among companies with meaningful Price/Projected FCF only.
ISRG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.5  Med: 2.6 Max: 14.57
Current: 1.99
1.5
14.57
Price/DCF (Earnings Based) 1.18
ISRG's Price/DCF (Earnings Based) is ranked higher than
78% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. ISRG: 1.18 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.94
ISRG's Price/Median PS Value is ranked higher than
56% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ISRG: 0.94 )
Ranked among companies with meaningful Price/Median PS Value only.
ISRG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.94 Max: 2.13
Current: 0.94
0.31
2.13
Price/Graham Number 2.64
ISRG's Price/Graham Number is ranked lower than
55% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. ISRG: 2.64 )
Ranked among companies with meaningful Price/Graham Number only.
ISRG' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 3.52 Max: 8
Current: 2.64
1.8
8
Earnings Yield (Greenblatt) (%) 4.16
ISRG's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ISRG: 4.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISRG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 3.75 Max: 9.8
Current: 4.16
1.3
9.8
Forward Rate of Return (Yacktman) (%) 5.07
ISRG's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. ISRG: 5.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ISRG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.3  Med: 29.7 Max: 141.9
Current: 5.07
-0.3
141.9

More Statistics

Revenue (TTM) (Mil) $2,624
EPS (TTM) $ 18.55
Beta0.79
Short Percentage of Float4.09%
52-Week Range $502.01 - 727.25
Shares Outstanding (Mil)38.75

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,669 2,952 3,320
EPS ($) 20.66 24.76 27.27
EPS w/o NRI ($) 20.66 24.76 27.27
EPS Growth Rate
(3Y to 5Y Estimate)
15.60%
Dividends Per Share ($)
» More Articles for NAS:ISRG

Headlines

Articles On GuruFocus.com
What Is Value? Nov 11 2016 
Classic Value Investing vs. Dynamic Value Investing Nov 02 2016 
Olstein All Cap Value Fund 2nd Quarter Letter to Shareholders Sep 01 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Titan Medical: Greatly Undervalued Jul 20 2016 
Top Medical Companies Reach High Financial Strength Jul 19 2016 
Tech Companies Reach High Altman Z-Scores Jul 14 2016 
My Favorite Health Care Stocks Jul 12 2016 
The “Bribing the Purchasing Agent Model" - Part I Jul 11 2016 

More From Other Websites
What Smart Money Thinks about Intuitive Surgical, Inc. (ISRG)? Nov 30 2016
How to Play the Coming Robot Revolution Nov 25 2016
Hedge Funds Are Crazy About Norfolk Southern Corp. (NSC) Nov 25 2016
Trump Corporate Tax Cuts Could Really Help These 4 Large Cap Companies Nov 16 2016
What Is Value? Nov 11 2016
Intuitive Surgical Reports New Employee Option Grants for November 2016 Nov 10 2016
Intuitive Surgical Reports New Employee Option Grants for November 2016 Nov 10 2016
Becton, Dickinson (BDX) Beats on Q4 Earnings & Revenues Nov 03 2016
Luminex (LMNX) Misses Q3 Earnings Estimates, '16 View Up Nov 03 2016
Healthways (HWAY) Misses Q3 Earnings, Revenue Estimates Nov 03 2016
Integer (ITGR) Beats Earnings and Revenue Estimates in Q3 Nov 02 2016
Fresenius Medical (FMS) Q3 Earnings, Sales Beat Estimates Nov 02 2016
Abiomed (ABMD) Q2 Earnings Lag Estimates, Revenues Beat Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)